Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7186563 | 0.83 | TACR2 (0.49) | MEN1KMT2ATACR2NPC1CYP2C19 | |
| SCHEMBL4631267 | 0.83 | TACR2 (0.62) | TACR2DPP4 | |
| SCHEMBL4800637 | 0.81 | MEN1 (0.47) | MEN1KMT2ANPSR1RORCMCHR1 | |
| SCHEMBL27418056 | 0.79 | TACR2 (0.59) | TACR2 | |
| SCHEMBL7174179 | 0.79 | TACR2 (0.43) | KMT2ATACR2RORC | |
| SCHEMBL7180636 | 0.79 | TACR2 (0.43) | KMT2ATACR2RORC | |
| Hydrochloric Acid SCHEMBL4802792 | 0.78 | TACR2 (0.42) | KMT2ATACR2RORC | |
| Hydrochloric Acid SCHEMBL4800620 | 0.78 | TACR2 (0.42) | KMT2ATACR2RORC | |
| SCHEMBL30702474 | 0.77 | RORC (0.51) | MEN1KMT2ANPSR1RORCMCHR1 | |
| SCHEMBL31567123 | 0.77 | RORC (0.51) | MEN1KMT2ANPSR1RORCMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378521-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7223860-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-7038044-B1 | Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2006-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | ADH1C, ADH1A, ADH5 | MEN1 2209/4885KMT2A 1327/4885NPSR1 157/4885 |
| US-20060149058-A1 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | ADH1C, ADH1A, ADH5 | MEN1 2209/4885KMT2A 1327/4885NPSR1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.